{"filings":[{"id":193897,"accession_number":"0001193125-24-240034","cik":1733257,"company_name":"Finch Therapeutics Group, Inc.","ticker":"FNCHQ","form_type":"8-K","filed_at":"2024-10-21T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"Finch Therapeutics initiates Nasdaq delisting; plans SEC deregistration by Nov 11","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board determined to delist common stock from Nasdaq; Form 25 to be filed on or about Oct 31, 2024.","Delisting effective 10 days after Form 25 filing; trading to continue on OTC Markets Group.","Form 15 to be filed on or about Nov 11, 2024 to deregister under Exchange Act; reporting obligations suspended immediately.","Board cites cost savings from SEC reporting, Sarbanes-Oxley compliance, and prior non-compliance (public shell, market value deficiency).","Common stock suspended from Nasdaq since May 28, 2024 due to Nasdaq's public shell determination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210221,"accession_number":"0001193125-24-198362","cik":1733257,"company_name":"Finch Therapeutics Group, Inc.","ticker":"FNCHQ","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Jury awards Finch $25M upfront plus royalties in patent infringement verdict against Ferring","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Jury found Ferring willfully infringed on Finch/UMN patents for microbiome therapy Rebyota.","Damages include $25.0M upfront payment and $0.815M in running royalties through trial date.","Two claims (one from '309, one from '080 patents) were found invalid; remaining claims valid.","Finch expects Ferring to file post-trial motions and appeal the judgment.","Trial began Aug 5, 2024; verdict rendered Aug 9, 2024 in U.S. District Court for Delaware."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228504,"accession_number":"0001193125-24-146454","cik":1733257,"company_name":"Finch Therapeutics Group, Inc.","ticker":"FNCHQ","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Finch Therapeutics receives Nasdaq delisting notice; trading suspended May 28","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Listing Panel determined to delist Finch; company deemed a 'public shell' without an operating business.","Trading of common stock suspended at opening on May 28, 2024; Nasdaq will file Form 25-NSE after 45 days.","Common stock expected to trade on OTC market, but no assurance of prompt or continued trading."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228503,"accession_number":"0001193125-24-141816","cik":1733257,"company_name":"Finch Therapeutics Group, Inc.","ticker":"FNCHQ","form_type":"8-K","filed_at":"2024-05-17T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Finch Therapeutics receives additional delisting notice, requests transfer to Nasdaq Capital Market","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq issued Additional Staff Determination on May 14, 2024, for continued noncompliance with $5M MVPHS Rule.","Company failed to regain compliance by May 13, 2024 deadline; first flagged Nov 15, 2023.","Company also deemed a 'public shell'; appeal hearing held April 23, 2024, decision pending.","On May 15, 2024, Company requested transfer from Nasdaq Global Select to Nasdaq Capital Market; no guarantee of approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228502,"accession_number":"0001193125-24-085435","cik":1733257,"company_name":"Finch Therapeutics Group, Inc.","ticker":"FNCHQ","form_type":"8-K","filed_at":"2024-04-03T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Finch Therapeutics audit committee falls to 2 members; Nasdaq grants cure period until Mar 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Susan Graf resigned from board on March 26, 2024, reducing audit committee to 2 independent directors.","Nasdaq requires audit committee of 3 independent directors; company notified Nasdaq on March 28.","Nasdaq notice received April 2; company has until March 26, 2025 or next annual meeting to regain compliance.","If next annual meeting is before September 23, 2024, cure deadline is September 23, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247172,"accession_number":"0001193125-24-044511","cik":1733257,"company_name":"Finch Therapeutics Group, Inc.","ticker":"FNCHQ","form_type":"8-K","filed_at":"2024-02-23T23:59:59+00:00","items":["3.01","8.01"],"status":"ready","headline":"Nasdaq says Finch is a 'public shell', seeks delisting; company appeals","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Finch on Feb 16, 2024 that it believes the company is a public shell and continued listing is unwarranted.","Finch disagrees and has requested an appeal hearing, which automatically stays any suspension or delisting pending the hearing.","No assurance that the appeal will succeed or that Finch can maintain listing compliance.","Patent litigation trial vs. Rebiotix/Ferring reset from May 20 to Aug 5, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264609,"accession_number":"0001193125-23-279821","cik":1733257,"company_name":"Finch Therapeutics Group, Inc.","ticker":"FNCHQ","form_type":"8-K","filed_at":"2023-11-17T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Finch Therapeutics receives Nasdaq deficiency notice for MVPHS below $5M","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency letter Nov 15, 2023 for failing MVPHS Rule 5450(b)(1)(C) for 35 consecutive days.","Market value of publicly held shares below $5M minimum required for continued listing on Nasdaq Global Select Market.","Compliance period through May 13, 2024; must meet $5M threshold for 10 consecutive business days to regain compliance.","If non-compliant, company may consider transferring to Nasdaq Capital Market; delisting possible if not cured."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281851,"accession_number":"0001193125-23-183823","cik":1733257,"company_name":"Finch Therapeutics Group, Inc.","ticker":"FNCHQ","form_type":"8-K","filed_at":"2023-07-07T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Finch Therapeutics terminates Somerville lease; rent obligations ended June 30","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease for 10,500 sq ft first floor and 25,785 sq ft fourth floor at 200 Inner Belt Road terminated June 30, 2023.","Landlord NRL WCS 200 Inner Belt Prop, LLC executed new lease with third party, triggering termination.","Rent obligations ceased; full security deposit refunded to Finch per Termination Agreement.","Lease originally dated Dec 21, 2015, assigned to Finch Therapeutics, Inc."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300833,"accession_number":"0001193125-23-177539","cik":1733257,"company_name":"Finch Therapeutics Group, Inc.","ticker":"FNCHQ","form_type":"8-K","filed_at":"2023-06-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Finch Therapeutics regains compliance with Nasdaq minimum bid price requirement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received letter from Nasdaq on June 27, 2023 confirming regained compliance with Listing Rule 5450(a)(1).","Closing bid price was $1.00 or greater for 10 consecutive business days from June 12 to June 26, 2023.","Previously notified of deficiency on Dec 30, 2022; compliance deadline was June 28, 2023.","Nasdaq considers the compliance matter closed; no further action required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300832,"accession_number":"0001193125-23-173133","cik":1733257,"company_name":"Finch Therapeutics Group, Inc.","ticker":"FNCHQ","form_type":"8-K","filed_at":"2023-06-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Nicholas Haft resigns from Finch Therapeutics Board effective June 23, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nicholas Haft resigned from the Board, effective June 23, 2023.","Resignation was not due to any disagreement with the Company's operations, policies, or practices.","Board composition changes following Haft's departure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300831,"accession_number":"0001193125-23-164542","cik":1733257,"company_name":"Finch Therapeutics Group, Inc.","ticker":"FNCHQ","form_type":"8-K","filed_at":"2023-06-09T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Finch Therapeutics shareholders approve 1-for-30 reverse stock split; elect two directors","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Reverse stock split at 1-for-30 ratio approved by 40,212,819 votes for, 717,495 against.","Common stock to begin trading on post-split basis on June 12, 2023 under new CUSIP 31773D200.","Susan Graf and Chris Shumway elected as Class II directors through 2026; Graf 26,097,717 votes for, Shumway 24,013,503.","Annual meeting had 40,934,688 shares present (~85.02% of outstanding)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300830,"accession_number":"0001193125-23-156571","cik":1733257,"company_name":"Finch Therapeutics Group, Inc.","ticker":"FNCHQ","form_type":"8-K","filed_at":"2023-05-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Finch Therapeutics enters consulting agreement with former CEO Mark Smith; up to $150K performance pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Consulting agreement with former CEO Mark Smith effective May 25, 2023 for advisory services.","Compensation includes hourly cash rate and eligibility for performance-based cash payments.","Maximum aggregate performance payments of $150,000 tied to critical corporate objectives.","Performance metrics determined by Compensation Committee of Board of Directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300829,"accession_number":"0001193125-23-148134","cik":1733257,"company_name":"Finch Therapeutics Group, Inc.","ticker":"FNCHQ","form_type":"8-K","filed_at":"2023-05-18T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Finch Therapeutics enters contingent lease termination agreement for Somerville facility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease termination contingent on landlord signing new tenant lease for 36,285 sq ft at 200 Inner Belt Road, Somerville.","Termination date would be later of May 31, 2023 or three days after new lease execution.","If no new lease by June 30, 2023, agreement void and lease continues through September 2026.","Security deposit of $199,467 to be returned to Finch upon termination and surrender of premises.","Company represents no active subleases; prior sublease to Microbiome Health Research Institute has expired."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300828,"accession_number":"0000950170-23-021205","cik":1733257,"company_name":"Finch Therapeutics Group, Inc.","ticker":"FNCHQ","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Finch Therapeutics dismisses Deloitte, appoints Wolf & Company as new auditor effective May 12, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee approved dismissal of Deloitte and engagement of Wolf & Company, effective May 12, 2023.","Decision driven by goal of reducing ongoing costs related to annual audit.","Deloitte's reports for 2021 and 2022 contained no adverse opinion except a going concern explanatory paragraph.","Material weakness in internal controls as of Dec 31, 2019 was remediated as of Dec 31, 2021.","No disagreements or reportable events with Deloitte during 2021, 2022, and through May 8, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300827,"accession_number":"0000950170-23-020075","cik":1733257,"company_name":"Finch Therapeutics Group, Inc.","ticker":"FNCHQ","form_type":"8-K","filed_at":"2023-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Finch Therapeutics Q1 net loss $63.9M on impairment charges; new CEO/CFO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $63.9M in Q1 2023 vs $24.6M in Q1 2022; includes $32.9M IPR&D impairment and $13.1M long-lived asset impairment.","Cash and equivalents $41.7M as of Mar 31, 2023; expects to fund operations into 2025.","Clinical trial agreement with Brigham and Women's Hospital to evaluate CP101 in ulcerative colitis; topline data expected in 2025.","Executive leadership transition: Matthew Blischak to become CEO, Lance Thibault to become CFO effective May 16, 2023.","Safety analysis from discontinued PRISM4 trial showed no drug-related serious adverse events among 19 patients."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":107000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300826,"accession_number":"0000950170-23-014424","cik":1733257,"company_name":"Finch Therapeutics Group, Inc.","ticker":"FNCHQ","form_type":"8-K","filed_at":"2023-04-25T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Finch Therapeutics replaces CEO and CFO; Blischak appointed CEO effective May 16","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Mark Smith and COO Marc Blaustein terminated without cause, effective May 15, 2023; Smith resigns from board.","Matthew P. Blischak named CEO effective May 16; base salary $400k, target bonus 40%, option grant of 962,899 shares.","Lance Thibault (Danforth Advisors) named CFO effective May 16; paid hourly $525.","Former executives to remain as consultants under advisory agreements.","Company emphasizes foundational IP estate (over 70 issued patents) as key asset."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300825,"accession_number":"0000950170-23-013276","cik":1733257,"company_name":"Finch Therapeutics Group, Inc.","ticker":"FNCHQ","form_type":"8-K","filed_at":"2023-04-18T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Finch Therapeutics announces ulcerative colitis trial for CP101, amends UMN license","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Investigator-sponsored trial at Brigham and Women's Hospital comparing two doses of CP101 in mild-to-moderate ulcerative colitis; topline data expected in 2025.","Amendment to University of Minnesota license allows Finch to satisfy performance milestones via sublicensing, aligning with new partnership-focused strategy.","Finch exclusively licenses 13 issued patents and 7 patent applications covering human fecal microbe formulations and microbiota diversity methods.","Clinical trial designed to generate data on safety, PK, PD, and clinical efficacy, building on microbiome evidence in ulcerative colitis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320744,"accession_number":"0000950170-23-009487","cik":1733257,"company_name":"Finch Therapeutics Group, Inc.","ticker":"FNCHQ","form_type":"8-K","filed_at":"2023-03-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Finch Therapeutics Q4 net loss $27M, cash $71M; patent litigation progress, PRISM4 discontinued","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 $27.0M vs $19.1M in Q4 2021; FY2022 net loss $114.6M vs $58.2M in prior year.","Cash and equivalents $71.0M at Dec 31, 2022; estimated $43.3M at Feb 28, 2023; cash runway extended into 2025.","Discontinued PRISM4 Phase 3 trial for CP101 in recurrent C. difficile; database locked, no treatment-related SAEs.","Court adopted Finch's claim constructions for 7/8 terms in patent case vs Ferring/Rebiotix; jury trial set May 2024.","Repaid $16.2M debt to Hercules, subleased Hood Park facility, and launched Strain Bank for licensing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320743,"accession_number":"0000950170-23-001236","cik":1733257,"company_name":"Finch Therapeutics Group, Inc.","ticker":"FNCHQ","form_type":"8-K","filed_at":"2023-01-26T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Finch Therapeutics prepays $16.2M to Hercules Capital, terminates loan agreement","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["On Jan 25, 2023, prepaid $16.2M aggregate, including $330K prepayment charge (2.2%) and $825K end-of-term fee.","Loan originally provided up to $55M term loan; only $15M was borrowed under the agreement.","All obligations, covenants, and liabilities under the Loan Agreement discharged and agreement terminated.","Interest rate was variable (Prime plus 4.05%, floor 7.55%); interest-only period was through Dec 2024.","Prepayment uses cash; reduces debt but drains liquidity for Finch Therapeutics (FNCH)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320742,"accession_number":"0000950170-23-001046","cik":1733257,"company_name":"Finch Therapeutics Group, Inc.","ticker":"FNCHQ","form_type":"8-K","filed_at":"2023-01-24T23:59:59+00:00","items":["2.05","7.01","9.01"],"status":"ready","headline":"Finch Therapeutics ends Phase 3 CP101 trial, cuts 95% of staff to focus on IP monetization","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Discontinued PRISM4 Phase 3 trial of CP101 in recurrent C. difficile infection; cites capital outlook, slow enrollment, unauthorized IP use.","Workforce reduced by 77 employees (~95% of employee base); most roles end Feb 2023, some continued into May 2023.","Expected restructuring costs of approximately $4.1 million from severance, outplacement and related expenses; charges recorded in H1 2023.","Company holds over 70 issued U.S. and foreign patents microbiome therapeutics and will seek to realize value from its IP estate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320741,"accession_number":"0000950170-23-000285","cik":1733257,"company_name":"Finch Therapeutics Group, Inc.","ticker":"FNCHQ","form_type":"8-K","filed_at":"2023-01-06T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Finch Therapeutics receives Nasdaq deficiency notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency letter on Dec 30, 2022 for non-compliance with $1.00 minimum bid price requirement.","Has 180 calendar days (until June 28, 2023) to regain compliance by closing at $1.00+ for 10 consecutive days.","May be eligible for additional 180-day extension if it transfers listing to Nasdaq Capital Market.","Company may consider a reverse stock split to regain compliance, subject to board and shareholder approval.","No assurance compliance will be regained; failure could lead to delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338880,"accession_number":"0000950170-22-026337","cik":1733257,"company_name":"Finch Therapeutics Group, Inc.","ticker":"FNCHQ","form_type":"8-K","filed_at":"2022-12-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Chief Business & Legal Officer Joseph Vittiglio resigns; COO Marc Blaustein gets retention bonus and expanded role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joseph Vittiglio resigns as Chief Business and Legal Officer & Secretary, effective Dec 31, 2022.","COO Marc Blaustein assumes business development and investor relations responsibilities after Vittiglio's departure.","Blaustein receives a service-based cash bonus of $83,000, payable in two equal installments (Dec 2022, June 2023).","Blaustein eligible for performance-based cash bonuses up to $332,000 tied to critical corporate objectives set by Compensation Committee.","Service-based bonus repayment required if Blaustein leaves voluntarily (non-Good Reason) or is terminated for Cause before May 31, 2023 (first installment) or Dec 31, 2023 (second)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338879,"accession_number":"0000950170-22-024697","cik":1733257,"company_name":"Finch Therapeutics Group, Inc.","ticker":"FNCHQ","form_type":"8-K","filed_at":"2022-11-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Finch Therapeutics posts updated corporate presentation to website on November 14, 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Updated corporate presentation posted on November 14, 2022 under 'Events & Presentations' section of Finch's website.","Presentation covers general business update and microbiome pipeline; no specific financial or clinical data disclosed.","No earnings, guidance, or material operational milestones announced in this 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338878,"accession_number":"0000950170-22-024143","cik":1733257,"company_name":"Finch Therapeutics Group, Inc.","ticker":"FNCHQ","form_type":"8-K","filed_at":"2022-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Finch Q3 net loss $40.4M on $18.1M goodwill impairment; PRISM4 Phase 3 dosing ongoing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $40.4M vs $10.0M in Q3 2021 due to $18.1M goodwill impairment and $11.2M revenue decline from Takeda termination.","Cash and equivalents $85.3M at Sept. 30, 2022; expected runway into Q2 2024, including sublease inflows.","Patient dosing underway in PRISM4 Phase 3 trial of CP101 for recurrent C. diff; topline data anticipated H1 2024.","Howard Franklin appointed Chief Medical Officer; ASD program (FIN-211) suspended; exploring partnerships for IBD candidates."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":853000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356252,"accession_number":"0000950170-22-018005","cik":1733257,"company_name":"Finch Therapeutics Group, Inc.","ticker":"FNCHQ","form_type":"8-K","filed_at":"2022-09-01T23:59:59+00:00","items":["2.05","7.01","9.01"],"status":"ready","headline":"Finch Therapeutics cuts 37% workforce, suspends FIN-211 trial after Takeda deal ends","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reduces workforce by 50 employees (~37% of staff) to cut costs.","Suspends initiation of Phase 1 trial for FIN-211 (autism candidate).","Estimates $1.6M in severance and related expenses; charges expected in H2 2022.","Action follows termination of Takeda IBD collaboration and ongoing strategic review.","Restructuring substantially complete by Q4 2022; cash runway update to come."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356251,"accession_number":"0000950170-22-017792","cik":1733257,"company_name":"Finch Therapeutics Group, Inc.","ticker":"FNCHQ","form_type":"8-K","filed_at":"2022-08-25T23:59:59+00:00","items":["1.02","7.01","9.01"],"status":"ready","headline":"Takeda terminates collaboration; Finch regains full rights to IBD candidates FIN-524 and FIN-525","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Takeda terminated collaboration for convenience effective Nov 17, 2022; Finch regains worldwide rights to FIN-524 and FIN-525.","Finch received over $44M total from Takeda ($10M upfront, $4M milestones, over $30M R&D reimbursement).","Finch will receive royalty-free license to all data and intellectual property generated during the collaboration.","Finch is conducting a portfolio review and assessing financial and strategic impact of the termination.","No new revenue or guidance provided; future development path for IBD candidates uncertain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356250,"accession_number":"0000950170-22-016635","cik":1733257,"company_name":"Finch Therapeutics Group, Inc.","ticker":"FNCHQ","form_type":"8-K","filed_at":"2022-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Finch Therapeutics Q2 2022 net loss $22.7M; revenue down $2.5M YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $22.7M vs $15.2M in Q2 2021; R&D flat at $13.9M; G&A up to $8.2M.","Revenue fell primarily due to Takeda agreement amendment; prior period had $1.8M PPP loan gain.","Cash $104.7M as of June 30, 2022 (down from $133.5M Dec 2021); funds operations into Q1 2024.","On track to start enrollment in PRISM4 Phase 3 CP101 trial in H2 2022; topline data expected H1 2024.","PRISM-EXT results accepted for ACG 2022; FIN-211 IND submission on track for Q4 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-29.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":715000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374617,"accession_number":"0000950170-22-011723","cik":1733257,"company_name":"Finch Therapeutics Group, Inc.","ticker":"FNCHQ","form_type":"8-K","filed_at":"2022-06-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Finch Therapeutics stockholders elect three Class I directors and ratify Deloitte as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["36,785,341 shares (77.35% of outstanding) present at June 10, 2022 annual meeting.","Domenic Ferrante, Nicholas Haft, Samuel A. Hamood elected as Class I directors with >26.8M votes for each.","Ratification of Deloitte & Touche as auditor for FY2022 approved: 36,759,831 for, 20,585 against.","Broker non-votes of 7,987,710 on director election; none on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374616,"accession_number":"0000950170-22-009935","cik":1733257,"company_name":"Finch Therapeutics Group, Inc.","ticker":"FNCHQ","form_type":"8-K","filed_at":"2022-05-16T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Finch Therapeutics reports Q1 net loss of $24.6M; FDA lifts clinical hold on CP101","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA lifted clinical hold on CP101 IND; Phase 3 PRISM4 enrollment expected in H2 2022.","Q1 2022 net loss $24.6M vs $14.0M in Q1 2021; revenue fell due to Takeda amendment.","Secured $55M debt facility from Hercules Capital; $15M drawn at closing.","Workforce reduced ~20% to focus on CDI, ASD, and Takeda-partnered IBD programs.","Cash and equivalents $106.9M as of March 31, 2022; runway into Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":354000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374615,"accession_number":"0000950170-22-006581","cik":1733257,"company_name":"Finch Therapeutics Group, Inc.","ticker":"FNCHQ","form_type":"8-K","filed_at":"2022-04-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Finch Therapeutics announces FDA removal of clinical hold on CP101 IND; prepares to resume PRISM4 Phase 3 trial","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA lifted clinical hold on CP101 IND after Finch provided SARS-CoV-2 screening data and revised consent language.","CP101 is an oral microbiome therapeutic for recurrent C. difficile infection, in late-stage development.","PRISM4 enrollment to resume after manufacturing activities, quality updates, and FDA agreement on protocol amendment and validation package.","Timing update for PRISM4 and AUSPIRE Phase 1b trial of FIN-211 expected with Q1 2022 results."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374614,"accession_number":"0000950170-22-005787","cik":1733257,"company_name":"Finch Therapeutics Group, Inc.","ticker":"FNCHQ","form_type":"8-K","filed_at":"2022-04-19T23:59:59+00:00","items":["2.05","8.01","9.01"],"status":"ready","headline":"Finch Therapeutics cuts 20% of workforce (37 FTE); focuses on CDI and ASD after FDA clinical hold","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reduction of 37 full-time employees (~20% of workforce) approved by board on April 14, 2022.","Estimates ~$1.1M in one-time severance and related costs, recorded in Q2 2022.","Restructuring follows FDA clinical hold on CP101 (SARS-CoV-2 donor screening) and pause of chronic hepatitis B program.","Company has submitted complete response to FDA on clinical hold and awaits feedback.","Prioritizing recurrent C. difficile infection (CDI) and autism spectrum disorder (ASD) programs; Takeda-partnered IBD work continues."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393114,"accession_number":"0000950170-22-005242","cik":1733257,"company_name":"Finch Therapeutics Group, Inc.","ticker":"FNCHQ","form_type":"8-K","filed_at":"2022-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Finch Therapeutics Q4 2021 net loss $19.1M; PRISM4 trial on hold, CFO retiring","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $19.1M in Q4 2021 ($13.1M in Q4 2020); full year loss $58.2M ($39.3M in 2020).","Cash and equivalents $133.5M at Dec 31, 2021; expected to fund operations into mid-2023.","PRISM4 Phase 3 trial of CP101 in recurrent C. difficile remains on clinical hold; at least one quarter delay.","Paused development of CP101 for chronic HBV to focus on CDI and autism programs.","CFO Greg Perry to retire April 30, 2022; COO Marc Blaustein to serve as principal financial officer."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":354000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393113,"accession_number":"0001193125-22-061539","cik":1733257,"company_name":"Finch Therapeutics Group, Inc.","ticker":"FNCHQ","form_type":"8-K","filed_at":"2022-03-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Finch Therapeutics pauses Phase 3 PRISM4 trial; FDA clinical hold on CP101; dosing occurred while hold in effect","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA clinical hold letter Feb 24, 2022 requesting additional info on SARS-CoV-2 donor screening protocols.","Company paused enrollment in PRISM4 Phase 3 trial of CP101 for recurrent C. difficile infection.","Company informed FDA that participants were dosed while clinical hold was in effect; conducting a review of the matter.","FDA letter did not reference any adverse clinical outcomes in Finch's trials.","Company evaluating impact on timing of expected topline data readout from PRISM4."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393112,"accession_number":"0000950170-22-000180","cik":1733257,"company_name":"Finch Therapeutics Group, Inc.","ticker":"FNCHQ","form_type":"8-K","filed_at":"2022-01-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Finch Therapeutics reports preliminary cash of $133.5M as of Dec 31, 2021","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Preliminary cash and cash equivalents of approximately $133.5M as of Dec 31, 2021.","CEO Mark Smith to present at J.P. Morgan Healthcare Conference on Jan 13, 2022.","Updated corporate presentation posted on company website for investor meetings.","Year-end audit ongoing; final cash balance may differ from preliminary estimate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":411567,"accession_number":"0000950170-21-003931","cik":1733257,"company_name":"Finch Therapeutics Group, Inc.","ticker":"FNCHQ","form_type":"8-K","filed_at":"2021-11-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Finch Therapeutics Q3 2021 net loss $10.0M; CP101 Phase 2 shows 80.3% cure rate","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $10.0M for Q3 2021 (vs. $10.1M loss in Q3 2020); R&D expenses increased to $15.5M from $9.0M.","CP101 Phase 2 open-label trial: 80.3% sustained clinical cure at 8 weeks, 78.8% at 24 weeks in recurrent CDI.","Initiated enrollment in PRISM4 Phase 3 trial of CP101; topline data expected H1 2023.","Cash and equivalents $149.2M as of Sept 30, 2021; expected to fund operations into mid-2023.","CMO Zain Kassam stepped down; Debra Silberg named interim CMO; Marc Blaustein joined as COO; Al Hamood added to board."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":17726000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":411566,"accession_number":"0000950170-21-002176","cik":1733257,"company_name":"Finch Therapeutics Group, Inc.","ticker":"FNCHQ","form_type":"8-K","filed_at":"2021-10-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Finch Therapeutics posts Jefferies IBD Summit slides; no new material disclosures","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Furnished slides under Item 7.01 for Jefferies Virtual Next Generation IBD Therapeutics Summit held October 2021.","Presentation titled 'Harnessing the Genomic Revolution & Machine Learning to Pioneer Microbiome Therapeutics'.","No financial results, guidance, or pipeline updates provided in the filing.","Slides available on company website under Events & Presentations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":411565,"accession_number":"0001193125-21-291534","cik":1733257,"company_name":"Finch Therapeutics Group, Inc.","ticker":"FNCHQ","form_type":"8-K","filed_at":"2021-10-05T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Finch Therapeutics appoints Samuel Allen Hamood to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Hamood elected as Class I director effective Oct 1, 2021; also chairs new Finance Committee.","Annual cash retainers: $35,000 for Board, $5,000 for Finance Committee, $10,000 as chair.","Initial equity grant: option to buy 25,543 shares at $12.94, $200,000 fair value, 3-year vest.","Hamood serves as President and CAFO of Culligan International; 30+ years of finance experience.","Board determined Hamood qualifies as independent under SEC and Nasdaq standards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":430333,"accession_number":"0001564590-21-047668","cik":1733257,"company_name":"Finch Therapeutics Group, Inc.","ticker":"FNCHQ","form_type":"8-K","filed_at":"2021-09-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Finch Therapeutics posts updated corporate presentation on website","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation dated September 2021 titled 'Harnessing the Genomic Revolution & Machine Learning to Pioneer Microbiome Therapeutics'.","Available under 'Events & Presentations' in the Investors section of the company's website.","No specific financial or pipeline updates were disclosed in the filing; content of the slide deck is not summarized."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":430332,"accession_number":"0001564590-21-047253","cik":1733257,"company_name":"Finch Therapeutics Group, Inc.","ticker":"FNCHQ","form_type":"8-K","filed_at":"2021-09-08T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Finch Therapeutics appoints Marc Blaustein as COO effective Sept 8","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Marc Blaustein appointed COO, effective September 8, 2021.","Base salary of $400,000; target bonus of 40% of base salary; options for 150,000 shares vesting over 4 years.","Blaustein brings 20+ years biopharma experience, including roles at Dyax, Alkermes, and as CEO of NED Biosystems.","CEO Mark Smith says Blaustein's operational expertise will be valuable as Finch enters next phase of growth.","Severance includes 9 months salary (non-CIC) or 12 months salary (CIC) plus equity acceleration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":430331,"accession_number":"0001564590-21-042879","cik":1733257,"company_name":"Finch Therapeutics Group, Inc.","ticker":"FNCHQ","form_type":"8-K","filed_at":"2021-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Finch Therapeutics Q2 net loss $15.2M; cash $168.1M; Takeda accelerates UC program","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $15.2M vs $8.3M YoY; R&D expense $14.0M, G&A $5.9M.","Cash and equivalents $168.1M at June 30, 2021, expected to fund operations into mid-2023.","Takeda elected to accelerate leadership of FIN-524/TAK-524 ulcerative colitis program.","CP101 open-label PRISM-EXT topline data from >130 patients expected H2 2021.","Topline data from FIN-211 in ASD and CP101 in chronic HBV expected H2 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":6383000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":430330,"accession_number":"0001564590-21-042877","cik":1733257,"company_name":"Finch Therapeutics Group, Inc.","ticker":"FNCHQ","form_type":"8-K","filed_at":"2021-08-10T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Finch transfers FIN-524 ulcerative colitis program to Takeda for clinical development","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment (Aug 9, 2021) transfers primary development & regulatory responsibility for FIN-524/TAK-524 to Takeda ahead of Phase 1.","Finch received $10M upfront & $4M in milestones; eligible for up to $176M additional plus mid-to-high single-digit royalties.","Finch will provide technical support through Phase 1; joint Crohn's disease discovery continues.","TAK-524 is an orally administered consortia candidate targeting ulcerative colitis via immune modulation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":430329,"accession_number":"0001193125-21-236296","cik":1733257,"company_name":"Finch Therapeutics Group, Inc.","ticker":"FNCHQ","form_type":"8-K","filed_at":"2021-08-04T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Finch Therapeutics signs 10-year lease for 61K sq ft in Charlestown; base rent ~$4.5M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sub Finch Therapeutics Inc. leases ~61,139 sq ft office/lab at 100 Hood Park Drive, Charlestown, MA.","Initial term of 10 years from Rent Commencement Date (earlier of Jan 1, 2022 or operations start).","Annual base rent starts ~$4.5M, increasing 2.8% per year to max ~$5.8M during initial term.","Tenant improvement allowance of ~$14.8M; letter of credit ~$2.3M required as security deposit.","Option to extend Lease for one additional five-year term; right of first offer on nearby spaces."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}